MedTrace Logo

A Multidimensional Study on Articulation Deficits in Parkinsons Disease

NCT05754086 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2024-08-27

No results posted yet for this study

Summary

Articulatory deficits are present in most speakers with dysarthria, which negatively impacts their speech intelligibility, yet little is known about the relationship between articulatory movement and speech intelligibility. This study will examine the relationship between articulation measures, both acoustic and kinematic, and their relationship to perceptual measures (i.e., speech intelligibility and articulation ratings) in 30 individuals with dysarthria secondary to Parkinson's disease and 30 neurologically healthy adults of the same age. The findings will have implications for behavioral management.

Conditions

  • Parkinson Disease
  • Dysarthria, Hypokinetic

Interventions

BEHAVIORAL

Clear Speech

This behavioral modification asks participants to speak more clearly, as if they were "speaking to someone with a hearing loss".

BEHAVIORAL

Less Clear Speech

This behavioral modification asks participants to speak less clearly, as if they were "in a room with many people and they were mumbling something to the person next to them that they didn't want other people in the room to hear."

Sponsors & Collaborators

  • National Institute on Deafness and Other Communication Disorders (NIDCD)

    collaborator NIH

  • Florida State University

    lead OTHER

Principal Investigators

  • Yunjung Kim, Ph.D. · Florida State University

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-09
Primary Completion
2023-07-31
Completion
2023-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05754086 on ClinicalTrials.gov